Fiche société
NYU Langone Health
Traitements, essais et publications liés.
Traitements23programmes
Essais11liés
Publications49liées
SourceDBlocale
Traitements
23| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| AtorvastatinThis study uses the cholesterol lowering drug atorvastatin, also known as lipitor, to show reduction of avascular necrosis in steroid treated lupus patients. Avascular necrosis is a disease resulting from the loss of blood supply to the bones which can cause the bone to collapse. The collapse of bone may require a surgical replacement of the joint and can be disabling for life. Avascular necrosis is presently not preventable but research has shown that lipid lowering drugs such as lipitor can reduce or prevent avascular necrosis in animals. We therefore hypothesize that lipitor will reduce the incidence of avascular necrosis in lupus patients taking high dose steroids. | Lupus | Phase 2 | À vérifier | United States | À vérifier |
| HEAL-SLE: Holistic Energy for Alleviating Lupus SymptomsThe purpose of this study is to assess the efficacy, feasibility, and acceptability of Virtual Reiki therapy as a complementary treatment for patients with systemic lupus erythematosus (SLE). The study also aims to investigate the feasibility, acceptability, and adherence of integrating Virtual Reiki therapy within the healthcare system for patients with SLE. Participants receiving standard of care (SOC) treatment for SLE will continue SOC while receiving research-specific Virtual Reiki therapy once per week for 8 weeks. Each study session will be delivered remotely by a Certified Reiki Practitioner Level II or higher. | Lupus | Non applicable | Traitement symptomatique | United States | À vérifier |
| HydroxychloroquineWomen with antibodies to proteins called SSA/Ro and or SSB/La face a 2% chance of having a child with a life threatening heart condition regardless of whether they have very active lupus, are in remission, or have only vague symptoms. This heart problem is referred to as congenital heart block (the most serious being third degree complete block) and represents damage thought to be caused by these autoantibodies. The heart beats abnormally slowly and almost all children require permanent pacemakers before the age of 20. Importantly, women who have had one child with heart block have a ten-fold higher risk of having another child with the same heart condition. Unfortunately, even close monitoring by special techniques during pregnancy does not reverse complete heart block once it is observed. Thus, treatments aimed at prevention are critical. This study will evaluate for the first time whether hydroxychloroquine, a drug used by many patients with SLE, prevents the development of this heart condition. Data from laboratory experiments suggests that this drug, which crosses the placenta, may decrease the inflammation initiated by the passage of anti-Ro antibodies to the fetus. The study uses a Simon's 2-Stage design, and plans to enroll 19 patients in Stage 1 and 35 patients in Stage 2 if Stage 1 is successful. Patients can already be on hydroxychloroquine or will be started as soon as pregnancy is confirmed. The hope is that fewer than 3 cases of heart block will occur in Stage 1, and fewer than 6 cases will occur out of all 54 patients if Stage 2 is reached. The results of this study are expected to become an integral part of the counseling of women with anti-Ro/La antibodies who are considering pregnancy. | Lupus | Phase 3 | Immunomodulation + Traitement symptomatique | United States | À vérifier |
| MemantineDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Alzheimer, Migraine, Sclérose latérale amyotrophique | Phase 4 | Ralentissement de la progression | United States | À vérifier |
| MRI, VenipunctureThis study uses the cholesterol lowering drug atorvastatin, also known as lipitor, to show reduction of avascular necrosis in steroid treated lupus patients. Avascular necrosis is a disease resulting from the loss of blood supply to the bones which can cause the bone to collapse. The collapse of bone may require a surgical replacement of the joint and can be disabling for life. Avascular necrosis is presently not preventable but research has shown that lipid lowering drugs such as lipitor can reduce or prevent avascular necrosis in animals. We therefore hypothesize that lipitor will reduce the incidence of avascular necrosis in lupus patients taking high dose steroids. | Lupus | Phase 2 | À vérifier | United States | À vérifier |
| PET-MR ScanAfrican-Americans (AAs) have an increased prevalence of both Alzheimer's disease (AD) and vascular risk factors for AD such as diabetes and hypertension when compared to whites. However, in a recent community based study of non-demented elderly, black race was associated with higher amyloid burden after adjusting for vascular risk factors, suggesting the presence of additional physiological differences on AD-risk by race in the early stages of the disease. The purpose of this study is to test whether poor slow wave sleep (SWS) quantity (SWS duration) and quality (slow wave activity, SWA) is one of these physiological factors. To test these hypotheses, the investigators will perform community outreach in churches and community-based organizations in Brooklyn and other NYC boroughs with which we have created substantial ties in recent years. In consultation with community stakeholders, the investigators will recruit 150 cognitively normal AA elderly (age 60-75) and 60 age, sex, BMI, income and education matched non-Hispanic whites from the same geographical areas. Investigators will first perform a medical and cognitive evaluation (Visit 1). Participants will then undergo 2 nights of home sleep monitoring using an unattended device to exclude OSA, followed by 7 days of actigraphy with a sleep log to record sleep duration. Both devices will be returned by mail. Subjects with reported total sleep time (TST) between 5 and 10 hours and absence of moderate to severe OSA will be invited to perform a 2-night nocturnal polysomnography (NPSG) (Nights 1-2) and a PiB-PET MR scan (Visit 2). | Alzheimer | À vérifier | À vérifier | United States | À vérifier |
| PiBAfrican-Americans (AAs) have an increased prevalence of both Alzheimer's disease (AD) and vascular risk factors for AD such as diabetes and hypertension when compared to whites. However, in a recent community based study of non-demented elderly, black race was associated with higher amyloid burden after adjusting for vascular risk factors, suggesting the presence of additional physiological differences on AD-risk by race in the early stages of the disease. The purpose of this study is to test whether poor slow wave sleep (SWS) quantity (SWS duration) and quality (slow wave activity, SWA) is one of these physiological factors. To test these hypotheses, the investigators will perform community outreach in churches and community-based organizations in Brooklyn and other NYC boroughs with which we have created substantial ties in recent years. In consultation with community stakeholders, the investigators will recruit 150 cognitively normal AA elderly (age 60-75) and 60 age, sex, BMI, income and education matched non-Hispanic whites from the same geographical areas. Investigators will first perform a medical and cognitive evaluation (Visit 1). Participants will then undergo 2 nights of home sleep monitoring using an unattended device to exclude OSA, followed by 7 days of actigraphy with a sleep log to record sleep duration. Both devices will be returned by mail. Subjects with reported total sleep time (TST) between 5 and 10 hours and absence of moderate to severe OSA will be invited to perform a 2-night nocturnal polysomnography (NPSG) (Nights 1-2) and a PiB-PET MR scan (Visit 2). | Alzheimer | À vérifier | À vérifier | United States | À vérifier |
| Remotely Supervised Transcranial Direct Current Stimulation (RS - tDCS)Growing evidence suggests that vagal nerve stimulation (VNS) may be novel and effective in the management of the symptom burden of multiple sclerosis (MS) potentially by reducing inflammation and emotional distress, therefore improving overall well-being. We will complete a pilot study comparing transcutaneous auricular vagus nerve stimulation (taVNS) and transcutaneous cervical vagus nerve stimulation (tcVNS) to a standard intervention of dorsolateral prefrontal cortex (DLPFC) transcranial direct current stimulation (tDCS) as an active control. The primary outcome will be feasibility and the preliminary efficacy data concerning self-reported symptom reduction to inform the design of an intervention, and estimated power needed to complete a larger sham-controlled RCT. We will also measure heart rate variability (HRV), an easily obtained biomarker of vagus nerve stimulation (VNS), in correspondence to intervention response. | SEP | Non applicable | Immunomodulation + Traitement symptomatique | United States | À vérifier |
| Remotely Supervised Transcutaneous Auricular Vagus Nerve Stimulation (RS - taVNS)Growing evidence suggests that vagal nerve stimulation (VNS) may be novel and effective in the management of the symptom burden of multiple sclerosis (MS) potentially by reducing inflammation and emotional distress, therefore improving overall well-being. We will complete a pilot study comparing transcutaneous auricular vagus nerve stimulation (taVNS) and transcutaneous cervical vagus nerve stimulation (tcVNS) to a standard intervention of dorsolateral prefrontal cortex (DLPFC) transcranial direct current stimulation (tDCS) as an active control. The primary outcome will be feasibility and the preliminary efficacy data concerning self-reported symptom reduction to inform the design of an intervention, and estimated power needed to complete a larger sham-controlled RCT. We will also measure heart rate variability (HRV), an easily obtained biomarker of vagus nerve stimulation (VNS), in correspondence to intervention response. | SEP | Non applicable | Immunomodulation + Traitement symptomatique | United States | À vérifier |
| Remotely Supervised Transcutaneous Cervical Vagus Nerve Stimulation (RS - tcVNS)Growing evidence suggests that vagal nerve stimulation (VNS) may be novel and effective in the management of the symptom burden of multiple sclerosis (MS) potentially by reducing inflammation and emotional distress, therefore improving overall well-being. We will complete a pilot study comparing transcutaneous auricular vagus nerve stimulation (taVNS) and transcutaneous cervical vagus nerve stimulation (tcVNS) to a standard intervention of dorsolateral prefrontal cortex (DLPFC) transcranial direct current stimulation (tDCS) as an active control. The primary outcome will be feasibility and the preliminary efficacy data concerning self-reported symptom reduction to inform the design of an intervention, and estimated power needed to complete a larger sham-controlled RCT. We will also measure heart rate variability (HRV), an easily obtained biomarker of vagus nerve stimulation (VNS), in correspondence to intervention response. | SEP | Non applicable | Immunomodulation + Traitement symptomatique | United States | À vérifier |
| Transcranial Direct Current Stimulation (TDCS)The primary study objective is to measure the electrical fields evoked by tDCS using subjects who have implanted intracranial electrodes as part of their evaluation for epilepsy surgery. The measurements obtained in these subjects and their brain MRI will be employed to validate existing mathematical models. In the future, these refined models can be used to target tDCS to predetermined brain regions in healthy and subjects and patient populations. As described above in the safety section, the intensities of stimulation applied in this project are not expected to produce changes in brain function, are below intensities commonly applied in clinical trials, and fall well below safety limits suggested by animal studies. | Épilepsie | NA | À vérifier | United States | À vérifier |
| YOPD — Young Onset Parkinson's Disease Subtypes and Pathogenic MechanismsYoung Onset Parkinson's disease (YOPD) refers to a group of patients in which the disease starts earlier in life (before the age of 50 years) and has a profound impact on most of patient's life. Current knowledge regarding the mechanisms leading to development of Parkinson's disease in younger individuals is lacking, but their understanding is crucial for the successful design of therapeutic strategies and stratifying patients for clinical trials. With this research the investigators aim to clarify the contribution of relevant biological processes in patients with Young onset Parkinson's disease to help understanding disease mechanisms and biomarkers. | Parkinson | À vérifier | À vérifier | United States | À vérifier |
| HydroxychloroquineWomen with antibodies to proteins called SSA/Ro and or SSB/La face a 2% chance of having a child with a life threatening heart condition regardless of whether they have very active lupus, are in remission, or have only vague symptoms. This heart problem is referred to as congenital heart block (the most serious being third degree complete block) and represents damage thought to be caused by these autoantibodies. The heart beats abnormally slowly and almost all children require permanent pacemakers before the age of 20. Importantly, women who have had one child with heart block have a ten-fold higher risk of having another child with the same heart condition. Unfortunately, even close monitoring by special techniques during pregnancy does not reverse complete heart block once it is observed. Thus, treatments aimed at prevention are critical. This study will evaluate for the first time whether hydroxychloroquine, a drug used by many patients with SLE, prevents the development of this heart condition. Data from laboratory experiments suggests that this drug, which crosses the placenta, may decrease the inflammation initiated by the passage of anti-Ro antibodies to the fetus. The study uses a Simon's 2-Stage design, and plans to enroll 19 patients in Stage 1 and 35 patients in Stage 2 if Stage 1 is successful. Patients can already be on hydroxychloroquine or will be started as soon as pregnancy is confirmed. The hope is that fewer than 3 cases of heart block will occur in Stage 1, and fewer than 6 cases will occur out of all 54 patients if Stage 2 is reached. The results of this study are expected to become an integral part of the counseling of women with anti-Ro/La antibodies who are considering pregnancy. | Lupus | Phase 2 | Immunomodulation + Traitement symptomatique | United States | À vérifier |
| Transcranial Direct Current Stimulation (TDCS)The primary study objective is to measure the electrical fields evoked by tDCS using subjects who have implanted intracranial electrodes as part of their evaluation for epilepsy surgery. The measurements obtained in these subjects and their brain MRI will be employed to validate existing mathematical models. In the future, these refined models can be used to target tDCS to predetermined brain regions in healthy and subjects and patient populations. As described above in the safety section, the intensities of stimulation applied in this project are not expected to produce changes in brain function, are below intensities commonly applied in clinical trials, and fall well below safety limits suggested by animal studies. | Épilepsie | NA | À vérifier | United States | À vérifier |
| AtorvastatinThis study uses the cholesterol lowering drug atorvastatin, also known as lipitor, to show reduction of avascular necrosis in steroid treated lupus patients. Avascular necrosis is a disease resulting from the loss of blood supply to the bones which can cause the bone to collapse. The collapse of bone may require a surgical replacement of the joint and can be disabling for life. Avascular necrosis is presently not preventable but research has shown that lipid lowering drugs such as lipitor can reduce or prevent avascular necrosis in animals. We therefore hypothesize that lipitor will reduce the incidence of avascular necrosis in lupus patients taking high dose steroids. | Lupus | Phase 2 | À vérifier | United States | À vérifier |
| PET-MR ScanAfrican-Americans (AAs) have an increased prevalence of both Alzheimer's disease (AD) and vascular risk factors for AD such as diabetes and hypertension when compared to whites. However, in a recent community based study of non-demented elderly, black race was associated with higher amyloid burden after adjusting for vascular risk factors, suggesting the presence of additional physiological differences on AD-risk by race in the early stages of the disease. The purpose of this study is to test whether poor slow wave sleep (SWS) quantity (SWS duration) and quality (slow wave activity, SWA) is one of these physiological factors. To test these hypotheses, the investigators will perform community outreach in churches and community-based organizations in Brooklyn and other NYC boroughs with which we have created substantial ties in recent years. In consultation with community stakeholders, the investigators will recruit 150 cognitively normal AA elderly (age 60-75) and 60 age, sex, BMI, income and education matched non-Hispanic whites from the same geographical areas. Investigators will first perform a medical and cognitive evaluation (Visit 1). Participants will then undergo 2 nights of home sleep monitoring using an unattended device to exclude OSA, followed by 7 days of actigraphy with a sleep log to record sleep duration. Both devices will be returned by mail. Subjects with reported total sleep time (TST) between 5 and 10 hours and absence of moderate to severe OSA will be invited to perform a 2-night nocturnal polysomnography (NPSG) (Nights 1-2) and a PiB-PET MR scan (Visit 2). | Alzheimer | À vérifier | À vérifier | United States | À vérifier |
| MemantineDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Phase 2 | Ralentissement de la progression | United States | À vérifier |
| Remotely Supervised Transcranial Direct Current Stimulation (RS - tDCS)Growing evidence suggests that vagal nerve stimulation (VNS) may be novel and effective in the management of the symptom burden of multiple sclerosis (MS) potentially by reducing inflammation and emotional distress, therefore improving overall well-being. We will complete a pilot study comparing transcutaneous auricular vagus nerve stimulation (taVNS) and transcutaneous cervical vagus nerve stimulation (tcVNS) to a standard intervention of dorsolateral prefrontal cortex (DLPFC) transcranial direct current stimulation (tDCS) as an active control. The primary outcome will be feasibility and the preliminary efficacy data concerning self-reported symptom reduction to inform the design of an intervention, and estimated power needed to complete a larger sham-controlled RCT. We will also measure heart rate variability (HRV), an easily obtained biomarker of vagus nerve stimulation (VNS), in correspondence to intervention response. | SEP | Non applicable | Immunomodulation + Traitement symptomatique | United States | À vérifier |
| YOPD — Young Onset Parkinson's Disease Subtypes and Pathogenic MechanismsYoung Onset Parkinson's disease (YOPD) refers to a group of patients in which the disease starts earlier in life (before the age of 50 years) and has a profound impact on most of patient's life. Current knowledge regarding the mechanisms leading to development of Parkinson's disease in younger individuals is lacking, but their understanding is crucial for the successful design of therapeutic strategies and stratifying patients for clinical trials. With this research the investigators aim to clarify the contribution of relevant biological processes in patients with Young onset Parkinson's disease to help understanding disease mechanisms and biomarkers. | Parkinson | À vérifier | À vérifier | United States | À vérifier |
| MemantineThe purpose of this study is to determine if memantine at up to 20 mg twice a day when used in conjunction with riluzole, can slow down the disease progression of patients with ALS including potentially improving their neuropsychiatric changes, as well as determine if serum biomarkers can be used both as a diagnostic and a prognostic marker in patients with ALS. Funding Source: FDA - Orphan Products Development (OPD) | Alzheimer | Phase 4 | Ralentissement de la progression | United States | À vérifier |
| HEAL-SLE: Holistic Energy for Alleviating Lupus SymptomsThe purpose of this study is to assess the efficacy, feasibility, and acceptability of Virtual Reiki therapy as a complementary treatment for patients with systemic lupus erythematosus (SLE). The study also aims to investigate the feasibility, acceptability, and adherence of integrating Virtual Reiki therapy within the healthcare system for patients with SLE. Participants receiving standard of care (SOC) treatment for SLE will continue SOC while receiving research-specific Virtual Reiki therapy once per week for 8 weeks. Each study session will be delivered remotely by a Certified Reiki Practitioner Level II or higher. | Lupus | Non applicable | Traitement symptomatique | United States | À vérifier |
| HydroxychloroquineWomen with antibodies to proteins called SSA/Ro and or SSB/La face a 2% chance of having a child with a life threatening heart condition regardless of whether they have very active lupus, are in remission, or have only vague symptoms. This heart problem is referred to as congenital heart block (the most serious being third degree complete block) and represents damage thought to be caused by these autoantibodies. The heart beats abnormally slowly and almost all children require permanent pacemakers before the age of 20. Importantly, women who have had one child with heart block have a ten-fold higher risk of having another child with the same heart condition. Unfortunately, even close monitoring by special techniques during pregnancy does not reverse complete heart block once it is observed. Thus, treatments aimed at prevention are critical. This study will evaluate for the first time whether hydroxychloroquine, a drug used by many patients with SLE, prevents the development of this heart condition. Data from laboratory experiments suggests that this drug, which crosses the placenta, may decrease the inflammation initiated by the passage of anti-Ro antibodies to the fetus. The study uses a Simon's 2-Stage design, and plans to enroll 19 patients in Stage 1 and 35 patients in Stage 2 if Stage 1 is successful. Patients can already be on hydroxychloroquine or will be started as soon as pregnancy is confirmed. The hope is that fewer than 3 cases of heart block will occur in Stage 1, and fewer than 6 cases will occur out of all 54 patients if Stage 2 is reached. The results of this study are expected to become an integral part of the counseling of women with anti-Ro/La antibodies who are considering pregnancy. | Lupus | Phase 3 | Immunomodulation + Traitement symptomatique | United States | À vérifier |
| MemantineThe purpose of this study is to determine if memantine at up to 20 mg twice a day when used in conjunction with riluzole, can slow down the disease progression of patients with ALS including potentially improving their neuropsychiatric changes, as well as determine if serum biomarkers can be used both as a diagnostic and a prognostic marker in patients with ALS. Funding Source: FDA - Orphan Products Development (OPD) | Alzheimer | Phase 2/3 | Neuroprotection + Ralentissement de la progression | Egypt | À vérifier |
Essais cliniques
11| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Memantine | Alzheimer | Phase 2/3 | NCT07504198 | Neuroprotection of Memantine and Rosuvastatin | NOT_YET_RECRUITING |
| Hydroxychloroquine | Lupus | Phase 3 | NCT05799378 | SHIELD — Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease | RECRUITING |
| HEAL-SLE: Holistic Energy for Alleviating Lupus Symptoms | Lupus | Non applicable | NCT07203157 | HEAL-SLE: Holistic Energy for Alleviating Lupus Symptoms | ACTIVE_NOT_RECRUITING |
| Memantine | Alzheimer | Phase 4 | NCT00933608 | Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease | COMPLETED |
| YOPD — Young Onset Parkinson's Disease Subtypes and Pathogenic Mechanisms | Parkinson | À vérifier | NCT07752355 | YOPD — Young Onset Parkinson's Disease Subtypes and Pathogenic Mechanisms | RECRUITING |
| Remotely Supervised Transcranial Direct Current Stimulation (RS - tDCS) | SEP | Non applicable | NCT06816004 | VANISH-MS — Noninvasive Vagal Nerve Stimulation | ACTIVE_NOT_RECRUITING |
| Memantine | Sclérose latérale amyotrophique | Phase 2 | NCT02118727 | Therapy in Amyotrophic Lateral Sclerosis (TAME) | COMPLETED |
| PET-MR Scan | Alzheimer | À vérifier | NCT03814603 | Sleep AWARE — The Sleep Amyloid, Slow WAve Race and Ethnicity Study | COMPLETED |
| Atorvastatin | Lupus | Phase 2 | NCT00412841 | Atorvastatin to Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus Erythematosus | TERMINATED |
| Transcranial Direct Current Stimulation (TDCS) | Épilepsie | NA | NCT02263274 | Direct Cortical Measurement of the Intensity and Pattern of Current Flow Produced by TDCS | COMPLETED |
| Hydroxychloroquine | Lupus | Phase 2 | NCT01379573 | Preventive Approach to Congenital Heart Block With Hydroxychloroquine | COMPLETED |
Publications
49| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Memantine | Treatment of animal models of Alzheimer's disease with extracellular vesicles or exosomes and involvement of microRNAs. | Neural regeneration research | ||
| Memantine | The multivariate genetic architecture of psychiatric and insulin resistance multimorbidity. | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology | ||
| Memantine | Pressure-induced suppression of supramolecular dynamics in hydrogen-bonded adamantane derivative. | Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy | ||
| Atorvastatin | High-throughput signal detection of hepatotoxic drug-drug interactions in hospitalized elderly patients: an NLP-driven pharmacovigilance study. | Annals of medicine | ||
| Atorvastatin | A ROS‑responsive liposome for atherosclerosis treatment via combined regulation of lipid metabolism and CD47 blockade. | International journal of pharmaceutics: X | ||
| Atorvastatin | Jianpi Qutan Formula attenuates vulnerable plaques by regulating IGFBP3. | Journal of ethnopharmacology | ||
| Hydroxychloroquine | Divergent neurobehavioral effects of hydroxychloroquine and leflunomide in a rat model of rheumatoid arthritis. | Neuropharmacology | ||
| Hydroxychloroquine | Treatment of discoid lupus erythematosus with crisaborole. | The Journal of dermatological treatment | ||
| Hydroxychloroquine | An explainable machine learning model for predicting in-hospital infection in patients with systemic lupus erythematosus. | Renal failure | ||
| Remotely Supervised Transcranial Direct Current Stimulation (RS - tDCS) | Telehealth tDCS to reduce cannabis use: A pilot RCT in multiple sclerosis as a framework for generalized use. | Drug and alcohol dependence | ||
| Memantine | Docking Analysis of Drugs Used in the Treatment of Alzheimer's Disease, Using Cell Membrane Receptors and Enzymes of the Kynurenine Pathway: A Pilot Study. | International journal of molecular sciences | ||
| MRI, Venipuncture | Secondary polycythemia as a rare cause of ischemic stroke: A case report. | Radiology case reports | ||
| MRI, Venipuncture | Iron overload cardiomyopathy. | Heart failure reviews | ||
| Atorvastatin | Atorvastatin Mitigates Hypercholesterolemia-Induced Alterations in Cerebral Mitochondrial Dehydrogenases in Rats. | International journal of molecular sciences | ||
| Atorvastatin | Comparative Effects of Different Statin Regimens on Postoperative Outcomes in Isolated Coronary Artery Bypass Grafting: A Propensity Score-Matched Analysis. | Journal of clinical medicine | ||
| Hydroxychloroquine | Eosinophilic Annular Erythema Completely Reactive to Dapson: A Case Report. | The Journal of dermatology | ||
| Hydroxychloroquine | Hydroxychloroquine Exposure Intensity During Early Pregnancy and Composite Fetal Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus: A Retrospective Cohort Study. | Journal of clinical medicine | ||
| Remotely Supervised Transcranial Direct Current Stimulation (RS - tDCS) | Low intensity transcranial electric stimulation: Safety, ethical, legal regulatory and application guidelines (2017-2025: An update) - endorsed by the European Society for Brain Stimulation (ESBS) and by the International Federation for Clinical Neurophysiology (IFCN). | Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology | ||
| Remotely Supervised Transcranial Direct Current Stimulation (RS - tDCS) | Exploring the Effects of Remotely Supervised Transcranial Direct Current Stimulation on Motor Outcomes in Multiple Sclerosis: A Systematic Review. | NeuroRehabilitation | ||
| Transcranial Direct Current Stimulation (TDCS) | Combined Functional Electrical and Transcranial Direct Current Stimulation for Foot Drop: A Case Series. | Journal of medical cases | ||
| PiB | Defect-Regulated Cubic Prussian Blue Analog Cathodes With Exceptional Stability for Potassium-Ion Batteries. | Small (Weinheim an der Bergstrasse, Germany) | ||
| PiB | High prevalence of tau pathologies in late-onset psychosis: A PET study. | Molecular psychiatry | ||
| PET-MR Scan | Angiogenesis PET/MRI predicts initial growth of sporadic vestibular schwannomas: a prospective study with follow-up in 29 patients using [Ga]Ga-NODAGA-E[c(RGDyK)]. | EJNMMI research | ||
| PET-MR Scan | Multimodal topographic properties of white matter functional segregation in Alzheimer's disease: A simultaneous PET/MR study. | European journal of radiology | ||
| Hydroxychloroquine | Symbiosis modulates pharmaceutical toxicity and contaminant fate in the Azolla-Nostoc system. | Chemosphere | ||
| Hydroxychloroquine | [Sarcoidosis-associated uveitis: Current status and future prospects]. | La Revue de medecine interne | ||
| Atorvastatin | Atorvastatin-associated neurological adverse events: a disproportionality analysis with adjustment for confounding by indication. | Frontiers in medicine | ||
| Transcranial Direct Current Stimulation (TDCS) | The Additive Effects of Transcranial Direct Current Stimulation Combined With Exercise-Based Rehabilitation Interventions on Balance, Ankle Kinematics, and Muscle Activity in Individuals With Ankle Instability: A Systematic Review. | Health science reports | ||
| Atorvastatin | High-Intensity Statin Treatment Is Associated With Reduced Growth Differentiation Factor-15 in Patients With Coronary Artery Disease. | European journal of clinical investigation | ||
| Atorvastatin | Statin Therapy and Outcomes in Heart Failure with Mildly Reduced Ejection Fraction. | Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese | ||
| Hydroxychloroquine | Cardiopulmonary Manifestations of Systemic Sclerosis: Pathophysiology, Clinical Presentation, and Management. | Cardiology in review | ||
| Hydroxychloroquine | A Rare Diagnostic Dilemma of P-ANCA/MPO Positive Crescentic Glomerulonephritis in an Immunosuppressed Lupus Patient. | Case reports in nephrology | ||
| Transcranial Direct Current Stimulation (TDCS) | Effects of concurrent transcranial direct current stimulation on human motor skill learning: A systematic review and Bayesian meta-analysis. | Behavioural brain research | ||
| Hydroxychloroquine | Hydroxychloroquine Retinopathy in Systemic Lupus Erythematosus: Risk Factors, Screening, and Emerging Biomarkers. | Journal of ophthalmology | ||
| Atorvastatin | Metabolic Mechanisms of Modified Lingguizhugan Decoction in Obesity and Lipid Metabolism Disorders: A Multi-Omics Approach. | Obesity science & practice | ||
| MRI, Venipuncture | Interesting neuroimaging findings in a child with hyperlipidemia: a case report. | BMC pediatrics | ||
| MRI, Venipuncture | Nurse led first seizure clinics-a dangerous experiment or an effective alternative to the norm? | Epilepsy & behavior : E&B | ||
| Atorvastatin | Sex-Dependent Vascular Responses to Atorvastatin Across Multiple Arterial Beds in a Mouse Model of Marfan Syndrome. | Cells | ||
| Atorvastatin | Muscle toxicity reports in FAERS: a disproportionality analysis with focus on rhabdomyolysis and cross-database assessment. | Frontiers in pharmacology | ||
| Hydroxychloroquine | Purpura as the initial manifestation of IgG4-related disease with concomitant systemic lupus erythematosus: a case report. | Frontiers in medicine | ||
| Hydroxychloroquine | Management of Uncomplicated Plasmodium vivax Malaria in a Pregnant Patient With G6PD Deficiency. | Cureus | ||
| Hydroxychloroquine | Nasal Manifestations of Immunoglobulin A (IgA) Vasculitis in an Adolescent Patient: A Case Report. | Cureus | ||
| Hydroxychloroquine | Atypical Lower Extremity Discoid Lupus Erythematosus Associated With Newly Diagnosed Systemic Lupus Erythematosus in a Male Patient: A Case Report. | Cureus | ||
| Hydroxychloroquine | Hydroxychloroquine-induced retinopathy in Puerto Ricans with systemic lupus erythematosus: Associated factors and early-onset risk. | Lupus | ||
| Hydroxychloroquine | Zeaxanthin Mitigates Hydroxychloroquine-Induced Retinal Toxicity and Metabolic Reprogramming in ARPE-19 Cells. | Journal of biochemical and molecular toxicology | ||
| Hydroxychloroquine | Diagnosis to dialogue: Reproductive health conversations and guideline adherence in women with lupus. | Lupus | ||
| Hydroxychloroquine | Treatments in oral lichen planus: a review. | Frontiers in oral health | ||
| Hydroxychloroquine | Agomelatine for Sjögren's syndrome: a study on its therapeutic effects and mechanisms. | Inflammopharmacology | ||
| Hydroxychloroquine | Targeting lysosomes with a novel chloroquine derivative induces irreversible lysosomal damage and disrupts autophagosome and lysosome assembly in cancer. | Autophagy |